On April 5, 2026, Soleno Therapeutics, Inc. entered into a merger agreement with Neurocrine Biosciences to offer $53.00 per share for its common stock, pending shareholder approval. The merger aims to strengthen both companies' positions in the market and is subject to specific conditions and regulatory approvals.